Additional Information

Description

Xgeva 120 mg/1.7 mL is a monoclonal antibody injection containing denosumab, a RANK ligand (RANKL) inhibitor. It is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors, the treatment of giant cell tumor of bone in adults and skeletally mature adolescents, and the management of hypercalcemia of malignancy refractory to bisphosphonate therapy.

Xgeva is administered as a subcutaneous injection at a recommended dose of 120 mg once every four weeks. Additional doses may be required for certain conditions, such as giant cell tumor of bone. Patients should receive supplemental calcium and vitamin D to reduce the risk of hypocalcemia. Common adverse reactions include fatigue, musculoskeletal pain, nausea, and dermatologic reactions.

Monitoring should include calcium, phosphorus, and magnesium levels, especially in patients with risk factors for hypocalcemia. Patients with renal impairment require close observation due to an increased risk of electrolyte disturbances. Hypersensitivity reactions, including anaphylaxis, may occur and require immediate medical intervention.